Bank of America’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14M | Sell |
646,068
-354,750
| -35% | -$7.66M | ﹤0.01% | 2698 |
|
|
2025
Q4 | $23.8M | Sell |
1,000,818
-359,963
| -26% | -$7.34M | ﹤0.01% | 2141 |
|
|
2025
Q3 | $18.5M | Buy |
1,360,781
+863,162
| +173% | +$8.97M | ﹤0.01% | 2692 |
|
|
2025
Q2 | $4.05M | Buy |
497,619
+246,048
| +98% | +$2.1M | ﹤0.01% | 4114 |
|
|
2025
Q1 | $1.97M | Buy |
251,571
+91,426
| +57% | +$1.06M | ﹤0.01% | 4699 |
|
|
2024
Q4 | $2.38M | Buy |
160,145
+19,232
| +14% | +$314K | ﹤0.01% | 4299 |
|
|
2024
Q3 | $2.15M | Sell |
140,913
-609
| -0.4% | -$9.6K | ﹤0.01% | 4495 |
|
|
2024
Q2 | $2.16M | Sell |
141,522
-8,030
| -5% | -$130K | ﹤0.01% | 4385 |
|
|
2024
Q1 | $2.82M | Sell |
149,552
-15,340
| -9% | -$265K | ﹤0.01% | 4165 |
|
|
2023
Q4 | $3.15M | Sell |
164,892
-27,919
| -14% | -$446K | ﹤0.01% | 3952 |
|
|
2023
Q3 | $3.46M | Buy |
192,811
+4,790
| +3% | +$96.2K | ﹤0.01% | 3745 |
|
|
2023
Q2 | $3.82M | Sell |
188,021
-961,197
| -84% | -$18.3M | ﹤0.01% | 3653 |
|
|
2023
Q1 | $21M | Buy |
1,149,218
+1,010,207
| +727% | +$19.3M | ﹤0.01% | 2080 |
|
|
2022
Q4 | $2.87M | Sell |
139,011
-10,466
| -7% | -$288K | ﹤0.01% | 3928 |
|
|
2022
Q3 | $3.91M | Buy |
149,477
+67,489
| +82% | +$1.78M | ﹤0.01% | 3595 |
|
|
2022
Q2 | $2.08M | Sell |
81,988
-55,473
| -40% | -$1.36M | ﹤0.01% | 4266 |
|
|
2022
Q1 | $4.34M | Buy |
137,461
+39,989
| +41% | +$1.34M | ﹤0.01% | 3781 |
|
|
2021
Q4 | $3.94M | Buy |
97,472
+28,802
| +42% | +$1.12M | ﹤0.01% | 3896 |
|
|
2021
Q3 | $2.39M | Buy |
68,670
+31,883
| +87% | +$992K | ﹤0.01% | 4269 |
|
|
2021
Q2 | $1.01M | Buy |
36,787
+4,770
| +15% | +$136K | ﹤0.01% | 4896 |
|
|
2021
Q1 | $899K | Sell |
32,017
-4,380
| -12% | -$152K | ﹤0.01% | 4923 |
|
|
2020
Q4 | $945K | Buy |
36,397
+6,879
| +23% | +$167K | ﹤0.01% | 4557 |
|
|
2020
Q3 | $506K | Sell |
29,518
-7,427
| -20% | -$166K | ﹤0.01% | 4703 |
|
|
2020
Q2 | $914K | Buy |
36,945
+16,194
| +78% | +$437K | ﹤0.01% | 4191 |
|
|
2020
Q1 | $288K | Sell |
20,751
-21,912
| -51% | -$273K | ﹤0.01% | 4873 |
|
|
2019
Q4 | $431K | Buy |
42,663
+7,488
| +21% | +$63K | ﹤0.01% | 5114 |
|
|
2019
Q3 | $321K | Sell |
35,175
-10,880
| -24% | -$87.4K | ﹤0.01% | 5371 |
|
|
2019
Q2 | $366K | Buy |
46,055
+18,419
| +67% | +$184K | ﹤0.01% | 5276 |
|
|
2019
Q1 | $346K | Buy |
27,636
+6,825
| +33% | +$74.1K | ﹤0.01% | 5233 |
|
|
2018
Q4 | $225K | Buy |
20,811
+18,240
| +709% | +$213K | ﹤0.01% | 5443 |
|
|
2018
Q3 | $36K | Buy |
2,571
+1,891
| +278% | +$24.1K | ﹤0.01% | 6343 |
|
|
2018
Q2 | $9K | Sell |
680
-1,882
| -73% | -$29.5K | ﹤0.01% | 6687 |
|
|
2018
Q1 | $40K | Buy |
+2,562
| New | +$42.7K | ﹤0.01% | 6125 |
|
Other funds holding RCUS
GS
SCM
VPM
VCM
WP
SL
Bank of America's RCUS Position: Q1 2026 in Review
Bank of America reduced its Arcus Biosciences (RCUS) stake by 35% in Q1 2026, selling an estimated $7.66M and leaving 646,068 shares worth $14M. The position accounts for ﹤0.01% of the portfolio, ranked #2698.
Bank of America first reported a position in RCUS in Q1 2018 and has held it in 33 quarters since. The position peaked at $23.8M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.
- Bank of America held 646,068 shares of Arcus Biosciences worth $14M as of Q1 2026.
- Bank of America sold 354,750 Arcus Biosciences shares in Q1 2026, an estimated $7.66M.
- Arcus Biosciences made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2698 holding.
- Bank of America first reported a position in Arcus Biosciences in Q1 2018 and has held it in 33 quarters since.
- Bank of America's Arcus Biosciences position peaked at $23.8M in Q4 2025.
- 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.